888 Seventh Avenue, 12th Floor,
New York, New York 10106
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
Join Mergr to view the latest updates and news from New York-based Aisling Capital.
In the last 3 years, Aisling Capital has invested in 1 company.
Aisling Capital’s most common sectors for investment are life science (66%) and medical products (25%). The Firm’s most common investment types include venture (66%) and buyout (lbo, mbo, mbi) (16%). In total, Aisling Capital has invested in 10 US states and 2 different countries. Its largest (disclosed) acquisition occurred in 2007 when it acquired Catalent for $3.3B.
In the last 3 years, Aisling Capital has exited 3 companies. The Firm’s most common exit type is trade sale (80%). Aisling Capital’s largest (disclosed) exit occurred in 2006 when it sold Myogen for $2.5B.
Join Mergr to view Aisling Capital’s full profile and discover more large private equity firms just like it.
No obligation. Cancel anytime.